2026-04-27T22:07:24Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/706352025-03-07T07:47:36Zcom_10324_1191com_10324_931com_10324_894col_10324_1379

00925njm 22002777a 4500 dc García Azorín, David author García Ruiz, Claudia author Sierra Mencía, Álvaro author González Osorio, Yesica author Recio García, Andrea author González Celestino, Ana author García Iglesias, Cristina author Planchuelo Gómez, Álvaro author Echavarría Íñiguez, Ana author Guerrero Peral, Angel Luis author 2024 To describe the need and effectiveness of acute and preventive medications in a series of 100 consecutive patients referred due to COVID-19-related headaches. Patients were aged 48.0 (standard deviation (SD): 12.4), 84% were female, and 56% had a prior history of headache. The most common headache phenotype was holocranial (63%), frontal (48%), pressing (75%), of moderate intensity (7 out of 10), and accompanied by photophobia (58%). Acute medication was required by 93%, with paracetamol (46%) being the most frequently used drug, followed by ibuprofen (44%). The drugs with the highest proportion of a 2 h pain-freedom response were dexketoprofen (58.8%), triptans (57.7%), and ibuprofen (54.3%). Preventive treatment was required by 75% of patients. The most frequently used drugs were amitriptyline (66%), anesthetic blockades (18%), and onabotulinumtoxinA (11%). The drugs with the highest 50% responder rate were amitriptyline (45.5%), mirtazapine (50%), and anesthetic blockades (38.9%). The highest 75% responder rate was experienced following onabotulinumtoxinA (18.2%). In conclusion, most patients required acute medication, with triptans and non-steroidal anti-inflammatory drugs achieving the best responses. Three-quarters of patients required preventive medication. The most frequently used drug was amitriptyline, which obtained the best results. In some treatment-resistant patients, anesthetic blockades and onabotulinumtoxinA were also beneficial. Life (Basel), 2024, vol. 14, n. 7, p. 910 https://uvadoc.uva.es/handle/10324/70635 10.3390/life14070910 910 7 Life 14 2075-1729 Acute and Preventive Treatment of COVID-19-Related Headache: A Series of 100 Patients